News

News

Press releases

March 21, 2018
Kyn Therapeutics Appoints Chairman and Scientific Advisory Board Member

December 14, 2017
Kyn Therapeutics Announces $49 Million Series A Capital Available to Develop Cancer Therapy Candidates with Novel Approaches to Major Immunometabolism Pathways

view all Tweets

Twitter

@KynTherapeutics
The amount of #immunooncology drugs in the pipeline is rapidly growing, with more than 2,000 clinical trials underw… http://J6CyeO4DmM

@KynTherapeutics
It's a new era at Kyn. We recently relocated to the Seaport to accommodate our growth. Check out our new digs! http://cVU0UNRete

@KynTherapeutics
How much do you know about the aryl hydrocarbon receptor (AHR)? It's a transcription factor linked to… http://aRrAKOG5gl

@KynTherapeutics
Our Senior Scientist @MartaSMBio was at #ASH18 this past weekend and had a great time connecting with colleagues in… http://IaYGouv9Qw

Media contact

Tom Donovan
Ten Bridge Communications
857-559-3397
tom@tenbridgecommunications.com

Alerts

Sign up to get up-to-date news about Kyn Therapeutics.

Contact us

Find us

Kyn Therapeutics
50 Northern Avenue
7th Floor
Boston, MA 02210

Call us

1-857-273-8343

Email us

info@kyntherapeutics.com

Friend us

LinkedIn